Endocrine Abstracts

We assessed glycemic status using oral glucose tolerance, 72-h continuous blood glucose concentrations by CGMS, calculate HOMA and QUICKI indices.Population: 15 adolescents with β thalassemia major.Results: Oral glucose tolerance test (OGTT) In the 15 thalassemic adolescents (age=19.75±3.08 years) showed that four had impaired fasting blood glucose level (IFG)>5.6 mmol/l. One of them had diabetes (BG=16.2 mmol/l at 2-...

Introduction: We evaluated glycemia and the iron status in patients with NT-SCD and 6 patients with TD- SCD by measuring serum ferritin level (SF), liver iron content (LIC), alanine transferase (ALT) and fasting blood glucose (FBG) over 5 years of follow up.Results: At the initial assessment, 16 adults with (age: 33±14 years), and six of TD-SCD (n=6, age =25±10 years) were studied. 6/16 of NT-SCD had SF > 500 μg/l, and 5/16 ha...

Introduction: Growth failure is the most frequent endocrine abnormality observed in patients with sickle-cell disease SCD. Decreased synthesis of IGF1 might be secondary to a disturbed GH–IGF1 axis and defective GH secretion has been reported in some patients. Infarction, atrophy, and hemorrhage may occur in the pituitary gland in SCD during or following the vaso-occlusive crisis.Objective: To define the possible abnormalities of pituitary gland in ...

Objectives: Elderly men often show a concurrence of a decline of testosterone with features of the metabolic syndrome.Materials and methods: One hundred and twenty-two men of a mean age of 59.5±6.0 years, with baseline testosterone 5.9–12.1 nmol/l were treated with parenteral testosterone undecanoate for 42 months as the sole intervention.Results: Plasma testosterone rose from 9.3±1.7 to 18.7±2.1 nmol/l reaching...

Objectives: To investigate the safety of the administration of long-acting parenteral testosterone undecanoate (TU) to hypogonadal, mainly elderly men.Design and methods: One hundred and twenty-two men of a mean age of 59.5±6.0 years, with baseline testosterone 5.9–12.1 nmol/l were treated with parenteral TU. These 122 patients were followed for 42 months.Results: Plasma levels of testosterone rose from 9.3±1.7 to 18...

Background: Despite available treatment for hypothyroidism, levothyroxine replacement therapy in a biochemically appropriate dose does not necessarily relieve patients’ symptoms and complaints. The aim of the study was to evaluate the concerns of patients treated with hypothyroidism and to correlate these concerns with different patient characteristics and thyroid biochemical control.Method: One hundred and eighteen treated primary hypothyroid patie...

Background: Vitamin D is a growing endemic problem. Wide proportions of healthy adults are deficient in vitamin D. It is very important for skeletal and non-skeletal health. It is now well established that many people have vitamin D levels that are less than currently recommended for optimal healthAim of this work: To assess vitamin-D sufficiency/deficiency in a sample of healthy Egyptian adult males in Dakahlia Governorate in Northern Egypt and correlat...

Introduction: Improvements of anthropometric and metabolic parameters on long-term testosterone replacement therapy (TRT) from our registry studies have been reported in 2013 (Saad, Obes; Yassin and Doros, Clin Obes; Traish, Int J Clin Pract).Methods: Five hundred and sixty-one hypogonadal men from both registry studies were divided into age groups ≤65 (Group A, n=450) and >65 years (Group B, n=111). All men were treated with ...

Introduction: Numerous studies have reported inverse associations between testosterone and obesity as well as other components of the metabolic syndrome.Methods: From two registry studies of 561 hypogonadal mens, 46 mens with obesity grade III (BMI ≧40 kg/m2) were selected. All patients received TU injections for up to 6 years. 46 mens were followed for 2 years, 43 for 3 years, 37 for 4 years, 34 for 5 years, and 24 for 6 s. Declining n...

Objective: To evaluate semen parameters and measure serum FSH, LH, Testosterone (T) concentrations before and 6 weeks after i.v. (800–1200 mg elemental iron iron therapy in adults with iron deficiency anemia.Patients and methods: This study investigated 11 adults with iron deficiency anemia (IDA) aged 40±5 years, with full pubertal development (Tanner stage 5, eugonadal) and capacity to ejaculate. They had iron deficiency anemia mainly due to d...